Short answer
Harmony Biosciences Holdings, Inc. (HRMY) filed its Q3 2025 10-Q quarterly report on Nov 4, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $239M (up 28.7% year over year) with net income of $51M.
Q3 2025 key financials · XBRL
- Revenue
- $239M
- +28.7% YoY · +19.4% QoQ
- Net income
- $51M
- +10.4% YoY · +27.9% QoQ
- Operating margin
- 27.3%
- Gross margin
- 75.1%
- EPS (diluted)
- $0.86
- +8.9% YoY · +26.5% QoQ
Source: XBRL data from the Harmony Biosciences Holdings, Inc. (HRMY) Q3 2025 10-Q on SEC EDGAR. USD.
Harmony Biosciences Holdings, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New clinical trial risk for Pitolisant PWS Phase 3 TEMPO study initiated Q1 2024 after FDA alignment Oct 2023 and Orphan designation Feb 2024
- Updated regulatory risk: FDA approved pediatric EDS label June 2024 but denied pediatric cataplexy sNDA; Type A meeting held Oct 2024 with resubmission Q3 2025
- Legal/compliance risk: ANDA litigation expenses included in general & administrative costs reflecting ongoing intellectual property challenges
- Operational risk: Pricing increased 7.0% Jan 2025 but higher rebates (~5.1% for Q3 2025) partially offset net revenue gains impacting near-term sales growth
- Financial risk: Cost of goods sold rose 39.4% Q3 2025 due to higher royalties triggered by increased revenues, raising cost ratio to 24.9% from 23.0% in prior year quarter
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Harmony Biosciences Holdings, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.